DIRECTORY
BIOTECH
Pharmaclient

   

Quick Click ! Monthly news Home-Site Menu-Site Contactexpress Faqs Legends Companies Events Environment Memories Home-Biotech

Abcys | AB Science | Adocia | Advicenne Pharma | Affichem | Agate Bioservices | Aisa Therapeutics | Alfact Innovation | Alizé Pharma | Ambiotis | Anaconda Pharma | Aptys Pharmaceuticals | Ariana Pharmaceuticals | Aterovax | Atlantic Bone Screen | Aureus Sciences | B Cell Design | BioAlliance Pharma | Biocortech | BioCydex | Biométhodes | Biom'up | BioProtein Technologies | BioQuanta | BioSystems International | BMSystems (Bio-Modeling) | Carmat | Cellectis | Cellial Technologies | CellProthera | CellVax | Cerenis Therapeutics | CliniGenetics | Covalab | Cytheris | Cytoo | DBV Technologies | Diaxonhit | DNA Therapeutics | Domain Therapeutics | Dynabio | Edelris | Endotis Pharma | Epixis | ERYtech Pharma | Eye Tech Care | Flamel Technologies | Fluofarma | GemacBio | Genepep | Genewave | Genfit | Genomic Vision | GenoSafe | GenoScience Pharma | Genoscreen | GenOway | Genticel | GTP Technology | Helios Biosciences | Hemarina | Hybrigenics | Hyphen BioMed | Imagene | ImmunId | Immutep | Imstar | In-Cell-Art | Indicia Biotechnology | InGen Biosciences | Innate Pharma | InnaVirVax | Innovative Health Diagnostics | IntegraGen | Ipsogen | I-Stem | Karcinolys | Keosys | MABlife | Magnisense | Mapreg | Mauna Kea Technologies | Medesis Pharma | Mellitech | Metabolys | MilleGen | Murigenetics | NanoBiotix | Neorphys | Neovacs | Netris-Pharma | Neuronax | NewVectys | NicOx | Nokad | Nosopharm | NovAliX | NovoCIB | Novotec | Obe Therapy | Oligovax | Oncodesign | OriBase Pharma | Oroxcell | Oxincell | Palumed | PharmaLeads | Pharnext | PhenoPro | Pherecydes Pharma | PolyIntell | Proteogenix | Protexel | PX'Therapeutics | Quantum Genomics | Rhenovia Pharma | ScarCell Therapeutics | Sisène Biotechnologies | Skuld-Tech | Stentys | Synapcell | Synprosis | Tc Land Expression | Theraclion | Theradiag | Theralpha | TheraVectys | Transgene | Trophos | TxCell | UROsphere | Vaxon Biotech | Vectalys | Vivalis | XenTech |

* DNA THERAPEUTICS *


 

2006 - IDF
Évry
(near Paris)
www.dna-therapeutics.com

 

Discovery, Drugs
Key words: Cancer, siDNA, DNA repair
Mission: to develop proprietary siDNA (signal interfering DNA) technology platform and molecules, interfering with DNA damage repair mechanisms, to fight treatment-resistant cancers
Clients: Prescribers
contact@dna-therapeutics.com

Age: 10 year(s)

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Personal venture |
Managing Dir.-CEO: Sun (Jian Sheg) [born 1959, also board chairman, Ph.D.]
Sc.Dir.-CSO: Sun (Jian Sheg)
Res.Dir.: Dutreix (Marie) [Ph.D, CNRS (Institut Curie)]
Fin.Dir.-CFO: Cervera (Bruno) [also, Actinnov (CEO), ex-Neurotech]
BusDev:
Financers (Hist.): Blue Medical Investment, Inserm Transfert

Turnover (M€) : n.a.
Total funding (M€) : 3.4
Last funding (M€) : 2.2
Focus : Cancers
Position : Preclin
Company confirm : none

 

History
DATEMILESTONETYPETIME
2011 .08 Clinical trial (phase I) for DT01 in cutaneous tumors (beginning, first dose completed in January, second dose in March) CLIN [5 years]
2011 .05 Financing (convertible bridge loan) : 2.0 M€, by OSEO, to support Dbait initial clinical trials DEBT [4 years]
2010 .10 Financing (grant) : 0.77 M€, by ANR, early stage clinical development of DT01 RFIN [4 years]
2010 .01 Patent (2nd) : granted on siDNA by USPTO (further secures the development of its lead product Dbait), followed 1 month later by European Patent Office (EPO), then China in 2011 LEGAL [3 years]
2009 .07 Financing (no interest loan) : 0.55 M€, by OSEO, to support CMC development of Dbait DEBT [3 years]
2009 .02 Research : publication in Clinical Cancer Research on Small-molecular drugs mimicking DNA damage (Dbait): a new strategy for sensitizing tumors to radiotherapy R&D [2 years]
2009 .01 1st round-financing : 2.2 M€, led by SGAM SEFTI with 2 previous seed investors, Blue Medical Investments and G1J-Île de France RFINA [2 years]
2008 .09 Seed financing : 0.8 M€, led by Inserm Transfer Initiative, with G1J-Île de France, Blue Medical Investment Group and International Business Angels (parallely to a patent granted on SiDNA) SFIN [2 years]
2007 .05 Patent : granted on siDNA by USPTA (secures the development of its lead product Dbait) LEGAL [0 year]
2006 .05 Company founded by Prof. Jian Sheg Sun, from concepts elaborated by Jean-Marc Cosset and Marie Dutreix, in 2001 ORGF [0 year]

Actualisation / Updating: 31-Oct-2012

   


Pharmaclient est le site-conseil de la Valorisation Client en Pharma...
Pour toute Mission, Inscription à la Pharmagalerie, Insertion dans la base Biotech, ou Question: CONTACT



© J.H. Huber, Pharmaclient 2001-2017. Pour retourner à la page d'accueil Biotech: BIENVENUE !       Haut de page : légende